A phase 2 Clinical trial entitled, 'Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients' by University of Kentucky has started recruiting for testing four arms:
Arm 1: Hydroxychloroquine
Arm 2: Hydroxychlorquine and Azithromycin
Arm 3: Hydroxychloroquine and Ivermectin
Arm 4: Camostat Mesilate
Total no of volunteers: 240
Primary outcome: Clinical Deterioration [ Time Frame: 14 days ]
Another clinical trial entitled, 'The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial' recruiting 580 participants, testing Camostat Mesilate, Camostat Mesilate, a Serine protease inhibitor that potentially blocks TMPRSS-2 mediated cell entry of SARS-CoV-2.
The primary outcome studied is: Days to clinical improvement from study enrolment [ Time Frame: 30 days ]
